These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 10694450)

  • 1. Antibody modeling: implications for engineering and design.
    Morea V; Lesk AM; Tramontano A
    Methods; 2000 Mar; 20(3):267-79. PubMed ID: 10694450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humanization of a highly stable single-chain antibody by structure-based antigen-binding site grafting.
    Villani ME; Morea V; Consalvi V; Chiaraluce R; Desiderio A; Benvenuto E; Donini M
    Mol Immunol; 2008 May; 45(9):2474-85. PubMed ID: 18313757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering.
    Ewert S; Honegger A; Plückthun A
    Methods; 2004 Oct; 34(2):184-99. PubMed ID: 15312672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody therapeutics, antibody engineering, and the merits of protein stability.
    Demarest SJ; Glaser SM
    Curr Opin Drug Discov Devel; 2008 Sep; 11(5):675-87. PubMed ID: 18729019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineering antibodies for stability and efficient folding.
    Honegger A
    Handb Exp Pharmacol; 2008; (181):47-68. PubMed ID: 18071941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canonical antigen-binding loop structures in immunoglobulins: more structures, more canonical classes?
    Decanniere K; Muyldermans S; Wyns L
    J Mol Biol; 2000 Jun; 300(1):83-91. PubMed ID: 10864500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic classification of CDR-L3 in antibodies: implications of the light chain subtypes and the VL-VH interface.
    Kuroda D; Shirai H; Kobori M; Nakamura H
    Proteins; 2009 Apr; 75(1):139-46. PubMed ID: 18798566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Energy-based analysis and prediction of the orientation between light- and heavy-chain antibody variable domains.
    Narayanan A; Sellers BD; Jacobson MP
    J Mol Biol; 2009 May; 388(5):941-53. PubMed ID: 19324053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative binding proteins: anticalins - harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities.
    Skerra A
    FEBS J; 2008 Jun; 275(11):2677-83. PubMed ID: 18435758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of humanized antibodies: from anti-Tac to Zenapax.
    Tsurushita N; Hinton PR; Kumar S
    Methods; 2005 May; 36(1):69-83. PubMed ID: 15848076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody humanization predicted by computer graphic analysis.
    Ramnarayan K; Skaletsky E
    Am Biotechnol Lab; 1995 Aug; 13(9):26, 28. PubMed ID: 7646845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leveraging SBDD in protein therapeutic development: antibody engineering.
    Gilliland GL; Luo J; Vafa O; Almagro JC
    Methods Mol Biol; 2012; 841():321-49. PubMed ID: 22222459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two and three-dimensional pattern recognition of organized surfaces by specific antibodies.
    Addadi L; Rubin N; Scheffer L; Ziblat R
    Acc Chem Res; 2008 Feb; 41(2):254-64. PubMed ID: 18217721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Model building of antibody combining sites.
    Bajorath J; Novotny J
    Ther Immunol; 1995 Apr; 2(2):95-103. PubMed ID: 8729880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody design: beyond the natural limits.
    Rees AR; Staunton D; Webster DM; Searle SJ; Henry AH; Pedersen JT
    Trends Biotechnol; 1994 May; 12(5):199-206. PubMed ID: 7764904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineering novel binding proteins from nonimmunoglobulin domains.
    Binz HK; Amstutz P; Plückthun A
    Nat Biotechnol; 2005 Oct; 23(10):1257-68. PubMed ID: 16211069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the antibody structure based on high-resolution crystallographic studies.
    Narciso JE; Uy ID; Cabang AB; Chavez JF; Pablo JL; Padilla-Concepcion GP; Padlan EA
    N Biotechnol; 2011 Sep; 28(5):435-47. PubMed ID: 21477671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineered antibodies take center stage.
    Huston JS; George AJ
    Hum Antibodies; 2001; 10(3-4):127-42. PubMed ID: 11847424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure and dynamics of the anti-AMCV scFv(F8): effects of selected mutations on the antigen combining site.
    Arcangeli C; Cantale C; Galeffi P; Rosato V
    J Struct Biol; 2008 Oct; 164(1):119-33. PubMed ID: 18662789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of aggregation prone regions of therapeutic proteins.
    Chennamsetty N; Voynov V; Kayser V; Helk B; Trout BL
    J Phys Chem B; 2010 May; 114(19):6614-24. PubMed ID: 20411962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.